Literature DB >> 17163840

Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.

J King1, N Thatcher, C Pickering, P Hasleton.   

Abstract

AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
METHODS: Nineteen relevant papers published during the period 1979-2005 were identified. Individual results of immunohistochemistry for five diagnostic antibodies were extracted to calculate diagnostic sensitivity and specificity. results from five of these studies that had evaluated proliferation markers or AgNOR staining techniques were also summarized.
RESULTS: Most antibodies demonstrated poor to moderate diagnostic ability. Desmin and epithelial membrane antigen (EMA) were the most useful, with sensitivity and specificity both above 74%. The combination of EMA and AgNOR was reported as having 95% diagnostic sensitivity. A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
CONCLUSIONS: Immunohistochemistry is of limited value, but newer diagnostic methods may be useful additions in this area of pathology. The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163840     DOI: 10.1111/j.1365-2559.2006.02442.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  12 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Authors:  Marcello Deraco; Dario Baratti; Antonello Domenico Cabras; Nadia Zaffaroni; Federica Perrone; Raffaella Villa; Jenny Jocollè; Maria Rosaria Balestra; Shigeki Kusamura; Barbara Laterza; Silvana Pilotti
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

Review 3.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

4.  Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.

Authors:  Andrey Bychkov; Vladimir Saenko; Masahiro Nakashima; Norisato Mitsutake; Tatiana Rogounovitch; Alyaksandr Nikitski; Florence Orim; Shunichi Yamashita
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

5.  Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.

Authors:  Daniel E Schwed Lustgarten; Jeffrey Thompson; Gordon Yu; Anil Vachani; Bhavesh Vaidya; Chandra Rao; Mark Connelly; Michelle Udine; Kay See Tan; Daniel F Heitjan; Steven Albelda
Journal:  Ann Am Thorac Soc       Date:  2013-12

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

7.  FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.

Authors:  Catherine T-S Chung; Gilda Da Cunha Santos; David M Hwang; Olga Ludkovski; Melania Pintilie; Jeremy A Squire; Ming-Sound Tsao
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

8.  p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.

Authors:  So-My Koo; Soo-Taek Uh; Dong Won Kim; Ki-Up Kim; Yang-Ki Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-06-28

9.  Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.

Authors:  Xiangyi Zan; Yuping Wang; Junnian Shi; Lanting Zhao; Yan Zhao; Rong Liu; Yongning Zhou; Yixin Wan
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

10.  Relapse with isolated peritoneal metastasis in lung adenocarcinoma: case report and review of the literature.

Authors:  Ozgur Tanriverdi; Sabri Barutca; Nezih Meydan
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.